other material
confidence high
sentiment positive
materiality 0.80
Hepion Phase 2 ALTITUDE-NASH trial meets primary endpoint with rencofilstat 225 mg improving liver function
Hepion Pharmaceuticals, Inc.
- Phase 2 trial met primary endpoint: 225 mg rencofilstat reduced DSI by 1.62 units (p<0.05) and SHUNT by 2.8% (p<0.05).
- 61% of 225 mg arm achieved ≥2-point DSI improvement (p<0.05); RISK ACE reduced 1.2 events/100 pt-yrs (p<0.001).
- Secondary endpoints: ALT ↓21.6%, AST ↓4.7%, ProC3 ↓9.6%, PIIINP ↓5.6%, ELF score ↓2.5% at 225 mg (all p<0.001).
- Rencofilstat well tolerated; no drug-related SAEs; supports ongoing Phase 2b ASCEND-NASH paired biopsy trial.